Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Raised to Hold at Zacks Research

Zacks Research upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC) from a strong sell rating to a hold rating in a research report report published on Thursday,Zacks reports.

A number of other equities analysts have also recently issued reports on BCYC. Needham & Company LLC cut their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wall Street Zen lowered Bicycle Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Friday, October 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $10.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 29th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.57.

Bicycle Therapeutics Stock Performance

Shares of Bicycle Therapeutics stock traded down $0.08 during trading hours on Thursday, reaching $3.37. The company’s stock had a trading volume of 604,366 shares, compared to its average volume of 408,886. The company’s 50 day simple moving average is $3.70 and its 200 day simple moving average is $4.42. Bicycle Therapeutics has a one year low of $3.26 and a one year high of $7.83. The stock has a market cap of $236.20 million, a P/E ratio of -1.66 and a beta of 1.59.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.25. Bicycle Therapeutics had a negative net margin of 169.75% and a negative return on equity of 26.02%. The business had revenue of $34.06 million during the quarter, compared to analyst estimates of $12.22 million. On average, sell-side analysts predict that Bicycle Therapeutics will post -2.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Marshall Wace LLP grew its holdings in Bicycle Therapeutics by 4.8% in the 3rd quarter. Marshall Wace LLP now owns 835,862 shares of the company’s stock worth $3,076,000 after buying an additional 37,922 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in Bicycle Therapeutics in the 3rd quarter valued at approximately $142,000. 49 Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the 3rd quarter valued at approximately $84,000. R Squared Ltd acquired a new stake in Bicycle Therapeutics in the 3rd quarter valued at approximately $98,000. Finally, Alps Advisors Inc. raised its stake in Bicycle Therapeutics by 30.1% during the 3rd quarter. Alps Advisors Inc. now owns 66,501 shares of the company’s stock valued at $245,000 after acquiring an additional 15,379 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.